Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

被引：0
作者：
Michael W. Jann
Kara L. Shirley
Gary W. Small
机构：
[1] Mercer University,Department of Clinical and Administrative Sciences, Southern School of Pharmacy
[2] Albany College of Pharmacy,Department of Pharmacy Practice
[3] University of California,Department of Psychiatry and Biobehavioral Sciences, Center on Aging and Alzheimer’s Disease Research Center
[4] Mercer University,Southern School of Pharmacy
来源：
Clinical Pharmacokinetics | 2002年 / 41卷
关键词：
Cholinesterase; Fluvoxamine; Cholinesterase Inhibitor; Rivastigmine; Tacrine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cholinesterase inhibitors are the ‘first-line’ agents in the treatment of Alzheimer’s disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity.
引用
收藏
页码：719 / 739
页数：20
相关论文
共 249 条
[1]  
Martin J.B.(1999)Molecular basis of the neurodegenerative disorders N Engl J Med 340 1970-80
[2]  
Parnetti L.(1997)Cognitive enhancement therapy for Alzheimer’s disease Drugs 53 752-68
[3]  
Senin U.(1999)Recent developments in the drug treatment of Alzheimer’s disease Drugs Aging 14 359-73
[4]  
Mecocci P.(2000)Cholinesterase inhibitors for the treatment of Alzheimer’s disease in the elderly Drugs Aging 16 123-36
[5]  
Sramek J.J.(1994)CNS nicotinic receptors CNS Drugs 2 216-33
[6]  
Cutler N.R.(2000)Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease Am J Med 109 577-85
[7]  
Van Den Berg C.M.(2000)Statins and the risk of dementia Lancet 356 1627-31
[8]  
Kazmi Y.(1997)Diagnosis and treatment of Alzheimer’s disease and related disorders JAMA 278 1363-71
[9]  
Jann M.W.(2001)Pharmacodynamic tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease CNS Drugs 15 375-90
[10]  
Court J.A.(2000)Cholinesterase inhibitors: a new class of psychotropic compounds Am J Psychiatry 157 4-15
12345678910